AKT1 and prostate carcinoma: Our earlier studies have shown that CTR increased growth and metastatic characteristics of the prostate cancer cells by multiple actions that included disruption of cell-cell junctions and activation of Gαs-mediated Wnt-β-catenin and PI3Kinase-Akt-survivin signaling pathways [11, 13].